| The cost-effectiveness of Pregabalin (lyrica®) in the treatment of severe fibromyalgia in the United States. |
| Author(s): Lloyd A1, Castelnuovo E1, Boomershine CS2, Choy E3, Chandran A4, Zlateva G4
|
| Affiliations(s): 1IMS Health, London, UK, 2Division of Rheumatology and Immunology, Vanderbilt University, Nashville, TN, USA, 3King's Musculoskeletal Clinical Trials Unit, King's College, London, UK, 4Pfizer Inc., New York, NY, USA |
| Publication(s): ISPOR 15th Annual International Meeting
May 15-19, 2010
Hilton Atlanta, Atlanta, GA, USA
|
| Document Type(s): Poster |
| Countries: USA |
| Click here for the abstract |
C:
Y: |
Musculoskeletal disease
2010 |
|
L:
A: |
English
Cost effectiveness |
|
 |
| |
| |
| Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective. |
| Author(s): Choy E1, Richards S2, Bowrin K3, Watson P3, Lloyd A3, Sadosky A4, Zlateva G4. |
| Affiliations(s): 1King’s Musculoskeletal Clinical Trials Unit, Academic Department of Rheumatology, King’s College, London,UK 2Poole Hospital NHS Foundation Trust, Poole, UK 3 IMS Health, Health Economics and Outcomes Research, London, UK 4 Pfizer Global Pharmaceuticals, New York, NY
|
| Publication(s): Curr Med Res Opin. 2010; 26(4): 965-975 |
| Document Type(s): Article |
| Countries: UK |
| Click here for the abstract |
C:
Y: |
Musculoskeletal disease
2010 |
|
L:
A: |
English
Cost effectiveness |
|
|
| |
| |
| Methods for interpreting tumor necrosis factor (TNF) blocker dosing and treatment patterns from pharmacy and professional claims. |
| Author(s): Makin C1, Schabert V2, Harrison DJ3, Goodman S4
|
| Affiliations(s): 1IMS Health, Plymouth Meeting, PA, USA, 2IMS Health, Santa Barbara, CA, USA, 3Amgen, Newbury Park, CA, USA, 4IMS Health, Watertown, MA, USA |
| Publication(s): ISPOR 15th Annual International Meeting, May 15-19, 2010, Atlanta, GA, USA
|
| Document Type(s): Poster |
| Countries: USA |
| Click here for the abstract |
C:
Y: |
Musculoskeletal disease
2010 |
|
L:
A: |
English
Methodology |
|
|
| |
| |
| GRAND: The German retrospective cohort analysis on non-adherence in osteoporosis: Analysis of repsistence with intravenous bisphosphonates in women |
| Author(s): Hadji P1, Claus V2, Kostev K3 Intorcia M4, Steinle T5 |
| Affiliations(s): 1 Klinik fur Gynakologie, Gynakologisch, Philipps-University, Marburg, Germany 2 Health Economics & Outcomes Research, IMS Health GmbH & Co. OHG, Munich, Germany 4 Centre of Excellence Patient Data, IMS Health GmbH & Co. OHG, Frankfurt am Main, Germany 5 Health Economics, Amgen GmbH, Munich, Germany |
| Publication(s): IOF World Congress on Osteoporosis & 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis
Florence, Italy, May 5-8, 2010 |
| Document Type(s): Abstract, Poster |
| Countries: Germany |
C:
Y: |
Medication compliance, Musculoskeletal disease
2010 |
|
L:
A: |
English
Retrospective cohort analysis |
|
|
| |
| |
| Non-adherence in women with osteoporosis treated with oral bisphosphonates: German retrospective cohort analysis on non-adherence (GRAND) |
| Author(s): Hadji P1, Claus V2, Steinle T3, Kostev K4, Intorcia M5 |
| Affiliations(s): 1 Philipps-University of Marburg, Marburg, Germany, 2 IMS Health GmbH & Co. OHG, Munich, Germany, 3 Amgen GmbH, Munich, Germany, 4 IMS Health GmbH & Co. OHG, Frankfurt am Main, Germany, 5 Amgen Europe GmbH, Zug, Switzerland |
| Publication(s): IOF World Congress on Osteoporosis & 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis
Florence, Italy, May 5-8, 2010 |
| Document Type(s): Abstract, Poster |
| Countries: Germany |
C:
Y: |
Medication compliance, Musculoskeletal disease
2010 |
|
L:
A: |
English
Retrospective cohort analysis |
|
|
| |
| |
| Non-compliance and associated risk of fracture in osteoporosis is patients treated with oral bisphosphonates: German retrospective cohort analysis on non-adherence (grand) |
| Author(s): Claus V1, Steinle T2, Kostev K3, Intorcia M4 |
| Affiliations(s): 1 Health Economics & Outcomes Research, IMS Health GmbH & Co. OHG, Munich, Germany 2 Health Economics, Amgen GmbH, Munich, Germany 3 Centre of Excellence Patient Data, IMS Health GmbH & Co. OHG, Frankfurt am Main, Germany, 4 iHE, Amgen (Europe) GmbH, Zug, Switzerland |
| Publication(s): IOF World Congress on Osteoporosis & 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis
Florence, Italy, May 5-8, 2010 |
| Document Type(s): Abstract, Poster |
| Countries: Germany |
C:
Y: |
Medication compliance, Musculoskeletal disease
2010 |
|
L:
A: |
English
Retrospective cohort analysis |
|
|
| |
| |
| Pregabalin is cost effective for FM: US and UK comparison |
| Author(s): Chandran AB1, Lui J1, Choy E2, Boomershine C2, Castelnuovo E3, Lloyd A3, Zlateva G1 |
| Affiliations(s): 1 Pfizer Inc, US 2 Vanderbilt University, US 3 IMS Health, London, UK |
| Publication(s): American Academy of Pain Management, 21st Annual Clinical Meeting, September 21-24, 2010, Caesars Palace, Las Vegas, Nevada, US |
| Document Type(s): Poster |
| Countries: UK, USA |
C:
Y: |
Musculoskeletal disease
2010 |
|
L:
A: |
English
Cost effectiveness |
|
|
| |
| |
| Health economic evaluation of outpatient management of fibromyalgia patients and the costs avoided by diagnosing fibromyalgia in France. |
| Author(s): Lamotte M, Maugars Y, Le Lay K, Taïeb C |
| Affiliations(s): |
| Publication(s): Clin Exp Rheumatol, 2010; 28 (Suppl. 63): S64-S70 |
| Document Type(s): Article |
| Countries: France |
C:
Y: |
Musculoskeletal disease
2010 |
|
L:
A: |
English
Economic evaluation |
|
|
| |
| |
| Cost-effectiveness of tapentadol prolonged-release (PR) compared to oxycodone and morphine in patients with chronic moderate to severe non-cancer pain in Sweden |
| Author(s): Hertel N1, Ikenberg R1, Fricke FU12, Liedgens H3 |
| Affiliations(s): 1IMS Health, Nuremberg, Germany 2Georg Simon Ohm University of Applied Sciences, Nuremberg, Germany 3Gruenenthal GmbH, Aachen, Germany |
| Publication(s): ISPOR November 6-9, 2010 Prague, Czech Republic |
| Document Type(s): Abstract |
| Countries: Sweden |
C:
Y: |
Health economics, Musculoskeletal disease
2010 |
|
L:
A: |
English
Cost benefit |
|
|
| |
| |
| The cost utility of autologous chondrocytes implantation using ChondroCelect in symptomatic knee cartilage lesions in Belgium. |
| Author(s): Gerlier L1, Lamotte M1, Wille M2, Kreuz PC3, Vanlauwe J4, Dubois D5, Meurgey FM6 |
| Affiliations(s): 1 IMS Health Consulting, Vilvoorde, Belgium 2 TiGenix NV, Leuven, Belgium 3 University Medical Center Rostock, Rostock, Germany 4 University Hospital Pellenberg, Leuven, Belgium 5 Patient Value Solutions, Huldenberg, Belgium 6 Oukelos SPRL, Brussels, Belgium |
| Publication(s): |
| Document Type(s): Article |
| Countries: Belgium |
C:
Y: |
Musculoskeletal disease
2010 |
|
L:
A: |
English
|
|
|
| |
| |
 2 of 4 
|
